Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $38
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
Alkermes Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Strong Performance and Clinical Promise Uphold Buy Rating for Alkermes With $32 Target Price
Buy Rating for Alkermes Supported by Strong Q2 Performance and Promising Pipeline Potential
Mind Medicine Price Target Maintained With a $36.00/Share by Roth MKM
Mind Medicine Analyst Ratings
Roth MKM Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $36
Compass Pathways Price Target Announced at $23.00/Share by RBC Capital
RBC Capital Initiates Coverage On Compass Pathways With Outperform Rating, Announces Price Target of $23
RBC Initiates COMPASS Pathways at Outperform, Speculative Risk With $23 Price Target
Intra-Cellular Therapies Analyst Ratings
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Alkermes Analyst Ratings
Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital
Intra-Cellular Therapies Analyst Ratings